Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFTRIAXONE DISODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J01D, J01DD) — coverage varies; not interchangeable

  • Cefixime (Suprax): general benefit
  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit

1 more in the class list below

Rocephin · DIN 00657387 · 0.25g/Vial · powder for injection, vial

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.Discontinued 2012-06-20 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Rocephin · DIN 00657387 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2012-06-20 · brand ROCEPHIN PWS INJ 0.25GM/VIAL · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 250 MG/VIAL · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Rocephin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8037 · Verify on the e-Formulary ↗ (DIN 00657387)

Source record
DIN 00657387: Rocephin Raw flags: notABenefit=Y, sec3=Y Item: 081228043; group id 41; item number 0087; lccId None; manufacturer id HLR Source form: Inj Pd-Vial Pk; strength: 0.25g/Vial Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00657387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8037
Interchangeable products
Ceftriaxone Sodium For Injection BP · DIN 02325594 · $5.6430 Ceftriaxone Sodium for Injection BP · DIN 02292262 · $5.6430
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2012-06-20 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, intra-abdominal infections, lower respiratory tract infections, skin and skin structure infections, urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 4 - Urinary tract infections (including those caused by Serratia marcescens and Serratia spp.) PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 6 - Bone and joint infections caused by Staphylococcus aureus PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit (1), Listed, not a benefit (1) • Skin and skin structure infections including cellulitis, abscesses, and wound infections when caused by Streptococcus pyogenes, Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Intra-abdominal infections including peritonitis and abdominal abscess when caused by susceptible anaerobes. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Bone and joint infections including osteomyelitis and septic arthritis when caused by sensitive strains of Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph AMOXICILLIN & CLAVULANIC ACID · General benefit (22), Listed, not a benefit (3) • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. PM: https://pdf.hres.ca/dpd_pm/00084428.PDF; date 2026-04-24; DIN 01916874; fetched 2026-09-10 Product monograph CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. • Bacterial Septicemia caused by E. coli, H. influenzae, K. pneumoniae, Staph. aureus and Strep. pneumoniae, (excluding enterococci). • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. • Meningitis caused by H. influenzae, N. meningitidis, and Strep. pneumoniae. Ceftriaxone sodium should not be used for the treatment of meningitis caused by L. monocytogen… https://pdf.hres.ca/dpd_pm/00071552.PDF PM date: MAY 15, 2023 Source product: CEFTRIAXONE FOR INJECTION; DIN 02289695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Rocephin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026